Introduction Rheumatoid arthritis (RA) represents a lucrative market, particularly because of the entrenched positioning of biologics in the treatment algorithm. A number of RA biologics have been…
Last Updated 14 December 2015 The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-α inhibitors have become firmly established as first-line biological agents, leaving…
The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate-to-severe rheumatoid arthritis (RA) has generated a multi-billion-…
Through comprehensive primary research methods, the TreatmentTrends: Rheumatoid Arthritis 2015 (US) report explores the treatment dynamics among 100 U.S. rheumatologists and how these have evolved…
ChartTrends: Rheumatoid Arthritis 2015 (US) provides insight into the management and treatment of RA patients by rheumatologists based on actual patient-level data. 224 U.S. rheumatologists…
For the estimated 2 million diagnosed patients in the United States who suffer from rheumatoid arthritis (RA), there are multiple prescription therapies that are available for treating the…
Juvenile idiopathic arthritis (JIA) is an autoimmune, rheumatologic disease characterized by joint inflammation, pain, and stiffness. JIA encompasses multiple forms of chronic arthritis in children…
For the estimated 1.6 million people in the United States who suffer from psoriatic arthritis (PsA), there are multiple prescription therapies that are available for treating the associated joint…
Physician and Payer Perspectives on Biologic Use and Novel Therapeutic Targets in the Treatment of Psoriatic Arthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis…
A Survey of Rheumatologists and Interviews with Payers in the EU5 Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that may…
Rheumatoid arthritis (RA) is a complex, chronic autoimmune condition that causes pain, stiffness, and swelling that, in moderate to severe cases, limits motion and functionality. The…
Chronic gout, estimated to affect 6.8 million U.S. adults, is a painful, inflammatory arthritis caused by high systemic levels of serum uric acid (sUA) resulting in hyperuricemia. Affected patients…
Where Are the Remaining Areas of Opportunity for Emerging Non-TNF Biologics and Oral Agents in the Increasingly Crowded Psoriatic Arthritis Market? The availability of tumor necrosis factor alpha…
Psoriatic arthritis (PsA) is an inflammatory joint disease that is highly comorbid with psoriasis, and characterized by pain, stiffness, and/or swelling in the joints, ligaments, and tendons. In…
Which Efficacy and Safety Achievements Will Differentiate Emerging Therapies in a Crowded Market Filled with Efficacious Drugs? Nine biologics are approved to treat rheumatoid arthritis (RA),…
